174 related articles for article (PubMed ID: 36357836)
1. MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer.
Zeng Z; He W; Jiang Y; Jiang H; Cheng X; Deng W; Zhou X; Zhang C; Wang G
BMC Cancer; 2022 Nov; 22(1):1162. PubMed ID: 36357836
[TBL] [Abstract][Full Text] [Related]
2. Scaffold protein MAPK8IP2 expression is a robust prognostic factor in prostate cancer associated with AR signaling activity.
Huang J; Liu W; Lin BY; Li JC; Lu J; Li BY
Asian J Androl; 2023; 25(2):198-207. PubMed ID: 35975362
[TBL] [Abstract][Full Text] [Related]
3. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
[TBL] [Abstract][Full Text] [Related]
4. SALL4 correlates with proliferation, metastasis, and poor prognosis in prostate cancer by affecting MAPK pathway.
Zhou J; Peng S; Fan H; Li J; Li Z; Wang G; Zeng L; Guo Z; Lai Y; Huang H
Cancer Med; 2023 Jun; 12(12):13471-13485. PubMed ID: 37119046
[TBL] [Abstract][Full Text] [Related]
5. A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition.
Bucay N; Bhagirath D; Sekhon K; Yang T; Fukuhara S; Majid S; Shahryari V; Tabatabai Z; Greene KL; Hashimoto Y; Shiina M; Yamamura S; Tanaka Y; Deng G; Dahiya R; Saini S
Cell Death Differ; 2017 Jul; 24(7):1263-1274. PubMed ID: 28498363
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.
Wang J; Cheng G; Li X; Pan Y; Qin C; Yang H; Hua L; Wang Z
Tumour Biol; 2016 Jul; 37(7):9603-13. PubMed ID: 26797783
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer.
Huang W; Su X; Yan W; Kong Z; Wang D; Huang Y; Zhai Q; Zhang X; Wu H; Li Y; Li T; Wan X
Prostate; 2018 Dec; 78(16):1248-1261. PubMed ID: 30105831
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.
Almeida M; Costa VL; Costa NR; Ramalho-Carvalho J; Baptista T; Ribeiro FR; Paulo P; Teixeira MR; Oliveira J; Lothe RA; Lind GE; Henrique R; Jerónimo C
J Cell Mol Med; 2014 Nov; 18(11):2287-97. PubMed ID: 25211630
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
10. Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer.
Meng X; Yuan H; Li W; Xiong Z; Dong W; Xiao W; Zhang X
IUBMB Life; 2021 Nov; 73(11):1363-1377. PubMed ID: 34549875
[TBL] [Abstract][Full Text] [Related]
11. MTSS1 hypermethylation is associated with prostate cancer progression.
Chen J; Huang L; Zhu Q; Wang Z; Tang Z
J Cell Physiol; 2020 Mar; 235(3):2687-2697. PubMed ID: 31541465
[TBL] [Abstract][Full Text] [Related]
12. SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis.
Yi C; Wan X; Zhang Y; Fu F; Zhao C; Qin R; Wu H; Li Y; Huang Y
Int J Biochem Cell Biol; 2018 Sep; 102():138-150. PubMed ID: 30053504
[TBL] [Abstract][Full Text] [Related]
13. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
14. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Du C; Lv C; Feng Y; Yu S
J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
[TBL] [Abstract][Full Text] [Related]
15. Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21.
Liang Z; Mou Q; Pan Z; Zhang Q; Gao G; Cao Y; Gao Z; Pan Z; Feng W
Med Oncol; 2019 May; 36(6):56. PubMed ID: 31089825
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of DDX49 in prostate cancer is associated with poor prognosis.
Tao J; Ge Q; Meng J; Liang C; Hao Z; Zhou J
BMC Urol; 2023 Apr; 23(1):66. PubMed ID: 37106339
[TBL] [Abstract][Full Text] [Related]
17. [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].
Yang M; Zhu X; Shen Y; He Q; Qin Y; Shao Y; Yuan L; Ye H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1109-1118. PubMed ID: 36073208
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
19. SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer.
Yuan D; Wang W; Su J; Zhang Y; Luan B; Rao H; Cheng T; Zhang W; Xiao S; Zhang M; Jiang FN; Sun Z; Jia Z; Zhong WD; Zhu J
Curr Cancer Drug Targets; 2018; 18(9):894-904. PubMed ID: 29295692
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis the diagnosis, malignant progression and immune infiltrate of ANXA6 in prostate cancer.
Huang B; Yang K
Genes Genomics; 2023 Sep; 45(9):1197-1209. PubMed ID: 37311953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
